| 形态 | Liquid |
|---|
| 宿主种属 | Human |
|---|
| 克隆性 | Monoclonal |
|---|
| 抗体亚型 | IgG4-kappa |
|---|
| 纯度 | >95% purity as determined by SDS-PAGE. |
|---|
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
|---|
| 浓度 | 1mg/ml |
|---|
| 内毒素水平 | Please contact the lab for this information. |
|---|
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| 种属反应性 | Human |
|---|
| 靶标 | Herpes virus entry mediator ligand, LIGHT, CD258, HVEM-L, HVEML, TNFSF14, Tumor necrosis factor ligand superfamily member 14, Herpesvirus entry mediator ligand |
|---|
| 储存缓冲液 | 0.01M PBS, pH 7.4. |
|---|
| 稳定性和储存 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| 表达系统 | Mammalian Cells |
|---|
| 登录号 | O43557 |
|---|
| 背景信息 | Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies.<br>• LIGHT (TNFSF14) enhances osteogenesis of human bone marrow-derived mesenchymal stem cells., PMID:33606781<br/>• LIGHT (TNFSF14) Increases the Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem Cells., PMID:27835685<br/>• Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth., PMID:9765287<br/>• A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis., PMID:10318773<br/> |
|---|
| 别名 | AEVI-002, CERC-002, F-19, MDGN-002, SAR-2520672427667-03-4 |
|---|
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
|---|